Management of Para-aortic Lymph Node Disease in Patients With Cervical Cancer What Is the Best Approach?
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
Editora
LIPPINCOTT WILLIAMS & WILKINS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, v.27, n.3, p.543-549, 2017
Resumo
Cervical cancer remains a prevalent and deadly disease in low-income countries, especially among young and otherwise healthy women. Multimodality treatment has led to a significant improvement in outcomes for patients with locally advanced disease, and this is mainly because of the incorporation of platinum-based chemoradiotherapy in current treatment protocols. However, locally advanced tumors are associated with a greater risk for para-aortic lymph node (PALN) involvement, which is an important adverse prognostic factor. Most staging techniques have low accuracy for detection of disease in this area, which could lead to understaging and undertreatment. Meanwhile, patients with PALN disease are underrepresented in trials addressing the treatment of advanced cervical cancer and a few studies have been directed at this population. The aim of this review is to analyze the current data regarding staging and treatment of cervical cancer with PALN disease to determine which strategy is best when managing these patients.
Palavras-chave
Cervical cancer, Para-aortic, Lymph nodes, Diagnosis, Treatment, Toxicity
Referências
- Barranger E, 2005, ANN ONCOL, V16, P1237, DOI 10.1093/annonc/mdi245
- BERMAN ML, 1984, GYNECOL ONCOL, V19, P8, DOI 10.1016/0090-8258(84)90151-3
- Brockbank E, 2011, COCHRANE DB SYST REV, V4
- Choi HJ, 2006, CANCER-AM CANCER SOC, V106, P914, DOI 10.1002/cncr.21641
- Chou HH, 2001, INT J RADIAT ONCOL, V51, P442, DOI 10.1016/S0360-3016(01)01628-5
- Chung YL, 2005, GYNECOL ONCOL, V97, P126, DOI 10.1016/j.ygyno.2004.12.039
- Du XL, 2010, CROAT MED J, V51, P229, DOI 10.3325/cmj.2010.51.229
- Ferlay J, 2013, GLOBOCAN 2012 V1 0 C, P11
- Fleming ND, 2015, GYNECOL ONCOL, V136, P48, DOI 10.1016/j.ygyno.2014.11.010
- Gouy S, 2013, J CLIN ONCOL, V31, P3026, DOI 10.1200/JCO.2012.47.3520
- Grigsby PW, 1998, INT J RADIAT ONCOL, V41, P817, DOI 10.1016/S0360-3016(98)00132-1
- Grigsby PW, 2001, INT J RADIAT ONCOL, V51, P982, DOI 10.1016/S0360-3016(01)01723-0
- Grigsby PW, 2001, J CLIN ONCOL, V19, P3745
- Grigsby PW, 2001, INT J RADIAT ONCOL, V49, P733, DOI 10.1016/S0360-3016(00)00806-3
- GRIGSBY PW, 1994, INT J RADIAT ONCOL, V28, P451
- Holcomb K, 1999, EUR J GYNAECOL ONCOL, V20, P90
- Howlader N, 2011, SEER CANC STAT REV 1
- Huang H, 2011, EJSO-EUR J SURG ONC, V37, P978, DOI 10.1016/j.ejso.2011.08.128
- Jang H, 2013, J GYNECOL ONCOL, V24, P229, DOI 10.3802/jgo.2013.24.3.229
- Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
- Jung J, 2014, ANTICANCER RES, V34, P4361
- Kim JS, 2003, INT J RADIAT ONCOL, V55, P1247, DOI 10.1016/S0360-3016(02)04401-2
- Kim YS, 2009, INT J RADIAT ONCOL, V74, P1522, DOI 10.1016/j.ijrobp.2008.10.024
- Lai CH, 2003, GYNECOL ONCOL, V89, P160, DOI 10.1016/S0090-8258(03)00064-7
- Lanciano R, 2005, J CLIN ONCOL, V23, P8289, DOI 10.1200/JCO.2004.00.0497
- Leblanc E, 2011, ANN SURG ONCOL, V18, P2302, DOI 10.1245/s10434-011-1583-9
- Leblanc E, 2007, GYNECOL ONCOL, V105, P304, DOI 10.1016/j.ygyno.2006.12.012
- Lecuru F, 2011, J CLIN ONCOL, V29, P1686, DOI 10.1200/JCO.2010.32.0432
- Li XL, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0352-5
- Lin WC, 2003, GYNECOL ONCOL, V89, P73, DOI 10.1016/S0090-8258(03)00058-1
- Marnitz S, 2015, STRAHLENTHER ONKOL, V191, P421, DOI 10.1007/s00066-014-0785-z
- Martinez A, 2010, GYNECOL ONCOL, V119, P76, DOI 10.1016/j.ygyno.2010.06.016
- Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430
- Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501
- Niibe Y, 2006, INT J RADIAT ONCOL, V66, P1366, DOI 10.1016/j.ijrobp.2006.07.1384
- Park SG, 2014, CANCER RES TREAT, V46, P374, DOI 10.4143/crt.2013.084
- Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P107, DOI 10.1016/j.ijgo.2009.02.009
- Quinn MA, 2015, INT J GYNECOL OBSTET, V95, pS43
- Ramirez PT, 2011, CANCER-AM CANCER SOC, V117, P1928, DOI 10.1002/cncr.25739
- Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2
- Rose PG, 2007, J CLIN ONCOL, V25, P2804, DOI 10.1200/JCO.2006.09.4532
- Rose PG, 1999, J CLIN ONCOL, V17, P41
- ROTMAN M, 1995, JAMA-J AM MED ASSOC, V274, P387, DOI 10.1001/jama.274.5.387
- Sakuragi N, 1999, CANCER, V85, P1547, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1547::AID-CNCR16>3.0.CO;2-2
- Selman TJ, 2008, CAN MED ASSOC J, V178, P855, DOI 10.1503/cmaj.071124
- Small W, 2007, INT J RADIAT ONCOL, V68, P1081, DOI 10.1016/j.ijrobp.2007.01.026
- Tillmanns T, 2007, GYNECOL ONCOL, V106, P370, DOI 10.1016/j.ygyno.2007.04.009
- Varia MA, 1998, INT J RADIAT ONCOL, V42, P1015, DOI 10.1016/S0360-3016(98)00267-3
- Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6
- Wu Y, 2013, MOL CLIN ONCOL, V1, P1025
- Yap ML, 2014, CLIN ONCOL-UK, V26, P797, DOI 10.1016/j.clon.2014.08.008
- Yildirim Y, 2008, GYNECOL ONCOL, V108, P154, DOI 10.1016/j.ygyno.2007.09.011
- Yoon HI, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-014-0320-5
- Zand B, 2010, GYNECOL ONCOL, V119, P422, DOI 10.1016/j.ygyno.2010.08.012